XNAS
ENTX
Market cap125mUSD
Oct 08, Last price
2.50USD
1D
-0.40%
1Q
51.06%
IPO
-60.32%
Name
Entera Bio Ltd
Chart & performance
P/E
—
P/S
2,933.94
EPS
—
Div yield, %
—
Shrs. gr., 5y
20.19%
Rev. gr., 5y
-35.11%
Revenues
42k
-76.80%
Net income
-11m
L+19.89%
CFO
-7m
L+8.10%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Key people
Dana Yaacov-Garbeli
Interim Chief Financial Officer · since 2019
Phillip Schwartz
Executive Vice President, President - Research & Development · since 2019
Arthur C. Santora
Chief Medical Officer · since 2018
David Ben Ami
Director · since 2014
Director · since 2016
Sean Ellis
Director · since 2019
Hillel Galitzer
Director
Roger J. Garceau
Director · since 2016
Director · since 2011
Independent Director · since 2018
Independent Chairman of the Board · since 2018
Gerald M. Ostrov
Independent Director · since 2019
Miranda Jayne Toledano
Independent Director · since 2018
Headquarters & legal address
5TH FLOOR
MINRAV BUILDING KIRYAT HADASSAH
JERUSALEM, JM 9112002
IL
MINRAV BUILDING KIRYAT HADASSAH
JERUSALEM, JM 9112002
IL
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||